Login to Your Account

Deals And M&A NEWS

Wave Life Sciences Ltd. has landed a $40 million up-front payment from Pfizer Inc. in a collaborative deal to develop genetically targeted therapies for metabolic diseases.

DUBLIN – Sanofi SA CEO Olivier Brandicourt turned up the heat on Medivation Inc. Thursday, by publicly releasing another letter to the company's board in support of its $9.3 billion cash bid.

Eight years after Ionis Pharmaceuticals Inc. selected then-independent Genzyme Corp. as the partner for its phase III lipid-lowering drug, mipomersen, in a potential $1.9 billion deal, the Carlsbad, Calif.-based company dealt the commercial asset, Kynamro, to start-up Kastle Therapeutics LLC for peanuts.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: